Cucurbitacin I induces pyroptosis via NF-κB/TNFR1/caspase-8/caspase-3/GSDME axis for cervical cancer treatment
- 1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 2Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Abstract
Purpose: Cervical cancer (CC) continues to pose a significant therapeutic challenge, ranking among the leading causes of morbidity and mortality in female reproductive malignancies. Cucurbitacin I (CuI), a natural compound, exhibits broad-spectrum anti-tumor activities, yet its effects and molecular mechanisms in CC remain unknown. This study aimed to investigate the anti-tumor efficacy of CuI in CC and to elucidate its underlying mechanisms.
Methods: To confirm that CuI induces pyroptosis in tumor cells, gene downregulation/knockdown and selective inhibition approaches were used to comprehensively evaluate cellular morphological features, gasdermin (GSDM) protein cleavage, and the activation status of the TNF-caspase signaling pathway. Additionally, the synergistic effect of CuI in combination with cisplatin was examined through drug synergy experiments. Finally, a mouse subcutaneous xenograft model was conducted to evaluate the tumor inhibitory and immunomodulatory effects of the drug treatment.
Results: CuI effectively reduced the survival rate of CC cells. Mechanistically, CuI induces pyroptosis in cervical cancer cells, as evidenced by distinctive morphological features and GSDME cleavage. This cleavage is driven by enhanced caspase-8/3 activity downstream of TNFR1. Mechanistically, CuI activates the NF-κB pathway, which upregulates TNF-α secretion and subsequently triggers the TNFR1-caspase-8 cascade. Additionally, when combined with cisplatin, CuI enhanced pyroptosis, which in turn activated antitumor immunity and increased tumor suppression both in vitro and in vivo.
Conclusion: CuI induces NF-κB/TNFR1/caspase-8/caspase-3/GSDME dependent pyroptosis and sensitizes cisplatin treatment in CC cells, which subsequently activates anti-tumor immune responses and contributes to tumor suppression in vivo.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13402-026-01274-7.
Related
- Bungarus multicinctus venom induces pyroptosis via the NLRP3/Caspase-1/GSDMD pathway in BV2 cells
- Gasdermin D-mediated delivery of caspase inhibitors to suppress pyroptosis
- Total secondary saponins from Anemone raddeana suppress pancreatic cancer via Caspase-3/GSDME-mediated pyroptosis.
- Nur77 Restrains Caspase-11-associated Macrophage Pyroptosis and Inflammatory Amplification During Early Sepsis
- IL10RB-AS1 promotes pro-caspase-1-dependent pyroptosis via regulating the oligomerization and nucleation of CARD8 C-terminal domain to suppress acute myeloid leukemia
BibTeX
@article{sun2026cucurbitacin,
title = {{Cucurbitacin I induces pyroptosis via NF-κB/TNFR1/caspase-8/caspase-3/GSDME axis for cervical cancer treatment}},
author = {Yue Sun and Danya Zhang and Yuxin Chen and Geyang Dai and Ling Xi},
journal = {Cellular Oncology},
year = {2026},
month = aug,
doi = {10.1007/s13402-026-01274-7},
url = {https://doi.org/10.1007/s13402-026-01274-7},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Cucurbitacin I induces pyroptosis via NF-κB/TNFR1/caspase-8/caspase-3/GSDME axis for cervical cancer treatment
AU - Yue Sun
AU - Danya Zhang
AU - Yuxin Chen
AU - Geyang Dai
AU - Ling Xi
PY - 2026
DA - 2026/08/07
JO - Cellular Oncology
DO - 10.1007/s13402-026-01274-7
UR - https://doi.org/10.1007/s13402-026-01274-7
AB - Purpose: Cervical cancer (CC) continues to pose a significant therapeutic challenge, ranking among the leading causes of morbidity and mortality in female reproductive malignancies. Cucurbitacin I (CuI), a natural compound, exhibits broad-spectrum anti-tumor activities, yet its effects and molecular mechanisms in CC remain unknown. This study aimed to investigate the anti-tumor efficacy of CuI in CC and to elucidate its underlying mechanisms. Methods: To confirm that CuI induces pyroptosis in tumor cells, gene downregulation/knockdown and selective inhibition approaches were used to comprehensively evaluate cellular morphological features, gasdermin (GSDM) protein cleavage, and the activation status of the TNF-caspase signaling pathway. Additionally, the synergistic effect of CuI in combination with cisplatin was examined through drug synergy experiments. Finally, a mouse subcutaneous xenograft model was conducted to evaluate the tumor inhibitory and immunomodulatory effects of the drug treatment. Results: CuI effectively reduced the survival rate of CC cells. Mechanistically, CuI induces pyroptosis in cervical cancer cells, as evidenced by distinctive morphological features and GSDME cleavage. This cleavage is driven by enhanced caspase-8/3 activity downstream of TNFR1. Mechanistically, CuI activates the NF-κB pathway, which upregulates TNF-α secretion and subsequently triggers the TNFR1-caspase-8 cascade. Additionally, when combined with cisplatin, CuI enhanced pyroptosis, which in turn activated antitumor immunity and increased tumor suppression both in vitro and in vivo. Conclusion: CuI induces NF-κB/TNFR1/caspase-8/caspase-3/GSDME dependent pyroptosis and sensitizes cisplatin treatment in CC cells, which subsequently activates anti-tumor immune responses and contributes to tumor suppression in vivo. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13402-026-01274-7.
SN - 2211-3428
SN - 2211-3436
ER -